Navigation Links
Lilly and Medtronic Announce Drug-Device Collaboration for Parkinson's Disease
Date:4/26/2011

INDIANAPOLIS and MINNEAPOLIS, April 26, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Medtronic, Inc. (NYSE: MDT) today announced they have entered into a collaboration to research and develop a new approach to treating Parkinson's disease that involves delivering a potential new  medicine to the brain using an implantable drug delivery system. The goal of the collaboration is to develop a therapeutic approach for Parkinson's disease that combines the strengths of Lilly's biologic, a modified form of glial cell derived neurotrophic factor (GDNF), with Medtronic's implantable drug infusion system technology.

"We believe we have biosynthetically engineered this GDNF variant to overcome technical hurdles of previous research in this area and are hopeful that early testing of our biologic with Medtronic's device will provide the necessary data to safely advance into human studies," said Michael L. Hutton, Ph.D., chief scientific officer of the neurodegeneration team at Lilly. "By collaborating with Medtronic from the earliest phase of research, we are maximizing the potential for this therapy's efficient and effective development."

Parkinson's disease is a neurodegenerative condition caused by progressive loss of neurons in the brain that produce dopamine, a chemical messenger responsible for transmitting signals that allow for coordination of movement. As a result, patients with Parkinson's disease experience balance problems, tremors and muscular stiffness, among other symptoms which worsen over time.  It is estimated that 7 million to 10 million people worldwide are living with Parkinson's disease(i) and there is no cure. Around the world, April is Parkinson's Awareness Month.

Applying its expertise in biotechnology, Lilly has designed its GDNF variant with th
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013  Hologic, Inc. ... ), a leading developer, manufacturer and supplier of ... with an emphasis on serving the healthcare needs ... observational study in a U.S. clinical practice comparing ... (breast tomosynthesis) with conventional 2D mammography alone showed ...
(Date:5/23/2013)... 23, 2013   Direct to implant, or ... an appropriate option for many women with BRCA ... their breast cancer risk, or with breast cancer. ... and a second surgery to insert permanent implants, ... surgery as mastectomy can be a medically and ...
(Date:5/23/2013)... , May 23, 2013  Net Medical Xpress ... telemedicine market, announced today the company has signed a ... staffing company based in Huntsville, AL ... specializes in the staffing and recruitment of telemedicine physicians. ... of the final agreement, which is expected by June ...
Breaking Medicine Technology:First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 2First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 3First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 4Direct to Implant ("One Step") Mastectomy Breast Reconstruction Reduces Number of Surgeries and Time to Final Cosmetic Results 2Direct to Implant ("One Step") Mastectomy Breast Reconstruction Reduces Number of Surgeries and Time to Final Cosmetic Results 3Net Medical Xpress Announces Acquisition of Telemedicine Staffing Company 2Net Medical Xpress Announces Acquisition of Telemedicine Staffing Company 3
... MINNEAPOLIS , May 3 Rescue Riders, a national ... to provide emergency medical assistance, has selected the HeartSine® samaritan® PAD ... , , ... more than 3,000 motorcycle-riding volunteers in 40 states who are trained ...
... , May 3 Par Pharmaceutical Companies, Inc. ... division, Par Pharmaceutical, has entered into an exclusive licensing agreement ... to market ezetimibe 10 mg tablets, the generic version ... is a cholesterol modifying agent with annual U.S. sales of ...
Cached Medicine Technology:Motorcyclist Volunteers Come to the Rescue With HeartSine AEDs 2Par Obtains Exclusive Rights to Market and Distribute Generic Zetia(R) in the U.S. 2Par Obtains Exclusive Rights to Market and Distribute Generic Zetia(R) in the U.S. 3
(Date:5/25/2013)... May 25, 2013 Pradaxa lawsuits ... life-threatening episodes of internal bleeding while using the blood thinner ... District Court, Southern District of Illinois, Bernstein Liebhard LLP reports. ... Pradaxa side effect claims had been filed in ... from 705 claims reported by the Court on May 15th. ...
(Date:5/25/2013)... According to a new market report,"Global Homeland ... MarketsandMarkets is expected to reach $544.02 Billion by ... and studies the major market drivers, restraints, and ... of the World. , Browse:, , ... 87 Figures , 175 Pages and ...
(Date:5/25/2013)... Acuity Games ’ innovative brain games have ... Word Hunt is available today, expanding it beyond its ... 2, Sudoku and Matchematics will roll out over the next ... lifetime brain fitness measurement have been re-optimized for the iPhone's ... brain fitness measurement in your pocket. What could be ...
(Date:5/25/2013)... For college students, few events can ... are turning to prescription stimulants like Adderall to ... on this, go to http://www.sciencedaily.com/releases/2013/05/130501145151.htm . , ... students who pick up Adderall, “just to help ... a physical and psychological dependency. While initially they ...
(Date:5/25/2013)... The current residents of Back2Basics - Long Term Drug and ... came together Saturday, May 18th to celebrate the company's 3rd ... residents got up to thank Roy Duprez, CEO and Founder ... recovery, and giving them a second chance at life. , ... realizing the need for a long-term facility. What started ...
Breaking Medicine News(10 mins):Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 2Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 3Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 2Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 3Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 4Health News:Acuity Games Apps Come to the iPhone 2Health News:Addiction and Drug Abuse: Study Drug Adderall Abuse Spikes During Finals 2Health News:Back2Basics Drug and Alcohol Rehabilitation Center Celebrates Their 3rd Anniversary 2
... Mother-Daughter Co-authors Share How Eating Disorders Affect Loved Ones At ... The Remuda Cornerstone Bookstore on May ... Disorders,( http://www.remudaranch.com ), the nation,s leading and largest inpatient,treatment center ... book signing event with the authors of the new book ...
... even within normal range associated with dangers , , TUESDAY, ... within the normal range may increase the risk of ... finds. , Thyrotropin, a hormone produced by the pituitary ... the thyroid gland to stimulate its growth and function. ...
... in German . , Leipzig. Unlike in ... Republic and Poland did not so far lead to massive ... there are other reasons for the presence of empty apartments, ... findings of a research project conducted by the Helmholtz Centre ...
... overall winner to launch Partner Enablement ... prepares for significant partner growth, ENGLEWOOD CLIFFS, N.J., ... recovery service provider and recent Gold,5-Star overall winner in ... Enablement Program at Interop 2008 in Las Vegas, NV,in ...
... 3,000,long-term care professionals are meeting in Columbus May ... personnel from skilled nursing facilities,assisted living residences, and ... The Ohio Health Care Association (OHCA), which represents ... state, is hosting its 62nd Annual,Convention & Exhibition ...
... Downs syndrome children who wear bifocal lenses to help them ... years, according to new research from Cardiff University. , The ... Unit has studied the reasons for poor focussing among children ... children in the study who adopted bifocals to ease difficulties ...
Cached Medicine News:Health News:Authors Of New Critically Acclaimed Book 'Distorted' Share Their Journey From an Eating Disorder at a Book Signing Event in Wickenburg 2Health News:Pituitary Hormone May Boost Women's Heart Risk 2Health News:Shrinkage and aging are Europe-wide challenges 2Health News:Shrinkage and aging are Europe-wide challenges 3Health News:Shrinkage and aging are Europe-wide challenges 4Health News:Intronis Technologies to Launch Partner Enablement Program at INTEROP 2008 2Health News:Ohio Health Care Association Hosts Midwest's Largest Long-Term Care Convention in Columbus 2Health News:A life 'lens' ordinary 2
Sub Pectoral Bra...
Bandeau Bra...
Post-Surgical compression garments...
... Cobalt Binding (ACB®) Test is a clinical ... (IMA®) by measuring the cobalt binding capacity ... First identified in the early 1990s, IMA ... contact with ischemic tissue in the heart. ...
Medicine Products: